Secukinumab may be associated with the worsening of CD; while the underlying cause and pathophysiological mechanisms have not been fully outlined, blocking IL-17A might interfere with its protective role in the intestine, which could be a possible explanation [46]. This evidence concerns the gene IL17A and Cowden disease.